FINWIRES · TerminalLIVE
FINWIRES

Edgewise Therapeutics Shares Decline Amid Wider Q1 Loss

By

-- Edgewise Therapeutics (EWTX) retreated more than 1% in morning trading Thursday as the company reported a wider Q1 loss.

The company reported a Q1 net loss of $0.46 per diluted share, compared with a loss of $0.43 a year earlier.

Four analysts polled by FactSet expected a loss of $0.49.

As expected, no revenue was reported for the quarter ended March 31.

The company said it had cash, cash equivalents and marketable securities of about $499.6 million as of March 31.

Price: $36.44, Change: $-0.55, Percent Change: -1.48%

Related Articles

Mining & Metals

RBC Maintains Suncor Energy's Outperform Rating, C$100 Price Target

RBC Capital Markets on Wednesday reiterated Suncor Energy's (SU.TO) outperform rating and C$100 price target, with the bank noting the company delivered another quarter of "robust performance" punctuated by a "jumbo-sized" downstream pre-tax margin of $2 billion (including FIFO gains) in part driven by record refined product sales of 680,900 bbl/d.RBC's updated production outlook of 862,100 bbl/d, anchored by a $5.7 billion capital program, remains relatively unchanged."Suncor's first-quarter results reinforced our confidence that its culture of sustained high performance is taking deep root and enabling the company to be on the podium, come what may," RBC said. "We believe the ingredients are in place for the company to earn a premium relative valuation, conceivably over the next year," RBC added.Suncor is RBC's favorite integrated producer in Canada and is part of its Global Energy Best Ideas list.Suncor traded at $85.70 per share at last look Thursday on the Toronto Stock Exchange.Price: $85.70, Change: $-2.21, Percent Change: -2.51%

$SU.TO
Australia

RBC Capital Adjusts VSE Price Target to $240 From $220, Maintains Outperform Rating

VSE (VSEC) has an average rating of Buy and mean price target of $248.50, according to analysts polled by FactSet.Price: $206.85, Change: $-0.60, Percent Change: -0.29%

$VSEC
Australia

RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating

United Therapeutics (UTHR) has an average rating of buy and mean price target of $670.67, according to analysts polled by FactSet.Price: $585.63, Change: $-11.14, Percent Change: -1.87%

$UTHR